Clinical Epidemiology Registers and Demography

Bendix Carstensen Steno Diabetes Center
Gentofte, Denmark
`http://BendixCarstensen.com`

,

Juni 2017

`http://BendixCarstensen.com`

Register studies (etc.)

- AstraZeneca contract:
    - CVD-real: Comparison of SGLT-2i inhibitors vs. any other drug in T2. Based on reconstructed DM reg, prescription register, propensity score matching:
        - Nordic arm: (DK, NO, SE) 1:3 matching
        - Global arm: (+UK, US, . . .) 1:1 matching
        - Global also DPP4 vs SGLT2 1:1. matched study

        We do the Danish data analysis, Main analysis with Statisticon, Uppsala.
    - Descriptive Epi (disease reality) (DK, FI, NO, SE):
      Incidence and mortality of drug treated DM, complication distribution at start, incidence of post-dx complications.
      Suboptimal complications event definition in NO, SE. Sensitivity analys witk DK data.

Register studies (etc.)

- Familial aggregation of DM
  (Jannie Nielsen — KU, Emory Atlanta)
- Adverse family events and incidence of T1D
  (Jessica Bengtsson — KU, UCL)

Both with help from Claus Ekstrøm, Biostat KU.

Register studies (etc.)

- ▶ Reconstructed NDR (spinoff of AZ proj):
  - ▶ Incidence / prevalence mortality
  - ▶ Components of prevalence (ADA 2017 poster)
  - ▶ Prediction of no. DM in future (EASD 2017 poster)
  - ▶ Prediction of undiagnosed / pre-DM from surveys (EASD 2017 poster)
  - ▶ Update of the DM-Ca study, including drug purchase as covariates.

Register studies (etc.)

- ▶ Collaboration with HongKong (**very** delayed from SDCC)
- ▶ Collaboration with Baker/IDI (Melbourne):
  - ▶ Mortality of AUS DM ptt. by age, duration and age at dx. (sumbission now)
  - ▶ BxC co-applicant on grant from AUS-NIHW (with CDC) to get an overview of incidence trends around the world. PI: Dianna Magliano
- ▶ Methods:
  - ▶ Maintain the Epi package for R — primarily for multistate processing and -analysis. Desperately needs publication on several topics (JSS).
  - ▶ Latent class methods (DtVs/GSA)
- ▶ Teaching all this stuff